51 results about "Riboswitch" patented technology

The present invention relates to methods for constructing a recombinant fungal host cell comprising one or more copies of a polynucleotide construct integrated in its genome, said method comprising transforming a fungal host cell with an integrative polynucleotide construct comprising a first polynucleotide encoding a selectable marker, wherein the first polynucleotide, a 5′ untranslated region thereof and / or a riboswitch operably linked therewith comprises a spliceosomal intron which has 5 nucleotides or less between its branch site and its acceptor site; and a second polynucleotide encoding a polypeptide of interest; as well as suitable polynucleotide constructs, resulting fungal host cells and methods of manufacture.

The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and / or anti-infectives. The invention also provides method of making novel flavin derivatives.

The present invention relates to methods for constructing a recombinant fungal host cell comprising one or more copies of a polynucleotide construct integrated in its genome, said method comprising transforming a fungal host cell with an integrative polynucleotide construct comprising a first polynucleotide encoding a selectable marker, wherein the first polynucleotide, a 5′ untranslated region thereof and / or a riboswitch operably linked therewith comprises a spliceosomal intron which has 5 nucleotides or less between its branch site and its acceptor site; and a second polynucleotide encoding a polypeptide of interest; as well as suitable polynucleotide constructs, resulting fungal host cells and methods of manufacture.

The invention discloses a reporting system for detecting the cyclic diguanylic acid (c-di-GMP) content in living cells and an application of the reporting system. The reporting system comprises a promoter, a riboswitch, an SD (Shine-Dalgarnosequence) sequence and a reporter gene which are connected in sequence. The application is characterized in that the reporting system is transferred into cells to be detected, reconstitution cells are placed into a culture solution for culture until the OD600 (Optical Density) of the culture solution reaches 0.4 to 0.6, then the expression quantity of the reporter genes in the recombinant cells is detected, and the cyclic diguanylic acid content in the cells to be detected is calculated according to the following formulas: cyclic diguanylic acid content=-1072ln (miller unit-CK) +793.35, wherein the miller unit represents the expression quantity of the reporter genes in the recombinant cells; and the CK represents the background level expression quantity of the reporter genes in the cells to be detected. By adopting the reporting system disclosed by the invention, the c-di-GMP content in the living cells can be conveniently detected; the operation method is simple, convenient and easy to implement; and the detection result is real and reliable.

Provided herein are libraries of scaffolds derived from riboswitches and small ribozymes and their methods of use. The scaffolds of the invention yield aptamers that are easily identified and characterized by virtue of the structural scaffold. The nature of the scaffold predisposes these RNAs for coupling to readout domains to engineer biosensors that function in vitro and in vivo. Biosensors, synthetic RNA agents and synthetic DNA agents, and their methods of use, are also provided.

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and / or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.

The invention relates to a recombinant plasmid for promoting glutathione synthesis by dynamically regulating ATP, an engineering bacterium and an application thereof, and belongs to the technical field of fermentation. In the invention, a gene recombination technology is utilized; firstly, a riboswitch ydaO module, a ppk gene, a gshf gene segment and a plasmid vector are recombined to construct arecombinant plasmid; and then, the recombinant plasmid is transferred into an escherichia coli competent state, and an ATP regulation and control method based on the riboswitch ydaO module and polyphosphokinase (ppk) is constructed in escherichia coli so that an ATP concentration can be controlled at a certain level, and synthesis of intracellular ATP dependent products is facilitated.

The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and / or anti-infectives. The invention also provides method of making novel flavin derivatives.

The TPP riboswitch is a target for antibiotics, herbicides, algicides, fungicides and other utilities. The atomic structure of the binding pocket of the TPP riboswitch has been resolved. Compounds identified and optimized using this information can be used to stimulate, activate, inhibit and / or inactivate the TPP riboswitch.

The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are alsocontemplated.

The invention discloses a gene control device and method based on CRISPR-Cas9. The device comprises a nucleotide sequence, wherein the nucleotide sequence is an sgRNA itself or can be transcribed into an sgRNA, the sgRNA structurally comprises a first part bonded with inactivated Cas9 protein and a second part connected to the 3'end of the first part, the 5'end of the first part is provided with an antisense sequence, and the second part is an aptamer sequence part which comprises a ligand binding part and an aptamer stem part; when no ligand exists, the aptamer sequence is pair-bonded with the aptamer stem part; when a ligand exists, the aptamer sequence is dissociated from the aptamer stem part so as to be pair-bonded with a target DNA. By integrating an RNA riboswitch bonded with a specific biological signal into the sgRNA, a bridge of cell signal intensity and gene expression intensity is established, any target gene can be activated or silenced on the basis that biological signal identification is achieved, and artificial connection is built between signal ligands and cytogene.